MenQuadfi

MenQuadfi Drug Interactions

vaccine, meningococcal

Manufacturer:

sanofi pasteur

Distributor:

DKSH
Full Prescribing Info
Drug Interactions
Use with other vaccines: Injection sites on separate limbs and separate syringes must be used in the case of concomitant administration.
For ages 12-23 months, MenQuadfi can be co-administered with the measles-mumps-rubella vaccine (MMR) and varicella vaccine (V), combined diphtheria - tetanus - acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B (HBV), inactivated poliovirus (IPV) or Haemophilus influenzae type b (Hib) such as DTaP-IPV-HB-Hib (Hib conjugated to tetanus toxoid) vaccine and 13-valent pneumococcal polysaccharide conjugated vaccine (PCV-13).
For ages 10-17 years, MenQuadfi can be co-administered with diphtheria, tetanus, pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content) (Tdap) and human papillomavirus vaccine (recombinant, adsorbed) (HPV).
MenQuadfi can be administered concomitantly with PCV-13. Lower hSBA GMTs on day 30 post-dose for serogroup A has been observed when given concommitantly. The clinical relevance of this observation is unknown. As a precaution in children 12-23 months of age at high risk for serogroup A disease, consideration might be given for administration of MenQuadfi and PCV-13 vaccines separately.
Meningococcal vaccine naïve children aged 10-17 years had non inferior response for PT and lower antibody responses to FHA, PRN and FIM when Tdap vaccine was administered concomitantly with MenQuadfi and HPV compared to co-administration with HPV vaccine alone. The clinical implications of the observed pertussis antigen responses also observed with the existing quadrivalent meningococcal conjugate vaccines are unknown.
Concomitant vaccines should always be administered at separate injection sites and preferably contralateral.
Concomitant administration of MenQuadfi and other vaccines than those listed previously has not been studied.
Use with systemic immunosuppressive medicinal products: It may be expected that in patients receiving immunosuppressive treatment an adequate immune response may not be elicited (see also Precautions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in